Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates

被引：1

作者：

Papadimitrakopoulou, Vassiliki ^{[1
]}

Redman, Mary ^{[2
]}

Gandara, David R. ^{[3
]}

Hirsch, Fred R. ^{[4
]}

Mack, Philipp ^{[5
]}

Borghaei, Hossein ^{[6
]}

Langer, Corey ^{[7
]}

Wade, James ^{[8
]}

Edelman, Martin ^{[9
]}

Albain, Kathy ^{[10
]}

Lara, Primo ^{[5
]}

Aggarwal, Charu ^{[11
]}

Socinski, Mark ^{[12
]}

Gettinger, Scott ^{[13
]}

Bazhenova, Lyudmila ^{[14
]}

Malik, Shakun ^{[15
]}

Miller, Vincent ^{[16
]}

Mcdonough, Shannon ^{[17
]}

Sigal, Ellen V. ^{[2
]}

Kelly, Karen ^{[18
]}

Herbst, Roy ^{[19
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Friends Canc Res, Washington, DC USA

[3] UC Davis Comprehens Canc Ctr, Div Hem Oncol, Sacramento, CA USA

[4] Univ Colorado, Ctr Canc, Other, Aurora, CO USA

[5] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[6] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[7] Univ Penn Hlth Syst, Hematol Oncol, Philadelphia, PA USA

[8] Heartland Ncorp, Decatur, IL USA

[9] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA

[10] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Div Hematol Oncol, Maywood, IL USA

[11] Univ Penn, Hematol Oncol, Philadelphia, PA 19104 USA

[12] Univ Pittsburgh, Med, Pittsburgh, PA USA

[13] Yale Canc Ctr, New Haven, CT USA

[14] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[15] NCI, Ctep, NIH, Rockville, MD USA

[16] Fdn Med Inc, Clin Dev, Cambridge, MA USA

[17] Swog Stat Ctr, Seattle, WA USA

[18] UC Davis Comprehens Canc Ctr, Hematol Oncol, Sacramento, CA USA

[19] Yale Canc Ctr, Med Oncol, New Haven, CT USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

genomic screening; umbrella trial; S1400; Squamous cell lung cancer;

D O I：

10.1016/j.jtho.2016.11.513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA16.10

引用

页码：S439 / S440

页数：2

共 47 条

[41] SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Aggarwal, Charu
Redman, Mary W.
Lara, Primo N., Jr.
Borghaei, Hossein
Hoffman, Philip
Bradley, Jeffrey D.
Newman, Alfred J., III
Feldman, Marvin J.
Minichiello, Katherine
Miao, Jieling
Mack, Philip C.
Papadimitrakopoulou, Vassiliki A.
Herbst, Roy S.
Kelly, Karen
Gandara, David R.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1847 - 1852
[42] A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A
Riess, J. W.
Miao, J.
Wheatley-Price, P.
Reckamp, K. L.
Kozono, D.
Redman, M. W.
Edelman, M. J.
Faller, B.
Villaruz, L.
Corum, L.
Gowda, A.
Srkalovic, G.
Osarogiagbon, R.
Baumgart, M.
Gandara, D. R.
Sokol, E. S.
Borghaei, H.
Gray, J. E.
Herbst, R. S.
Kelly, K.
ANNALS OF ONCOLOGY, 2024, 35 : S832 - S833
[43] A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non-small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).
Skoulidis, Ferdinandos
Redman, Mary Weber
Suga, Jennifer Marie
Al Baghdadi, Tareq
Villano, John L.
Goldberg, Sarah B.
Villaruz, Liza C.
Minichiello, Katherine
Gandara, David R.
Herbst, Roy S.
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[44] Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.
Reckamp, Karen L.
Redman, Mary Weber
Dragnev, Konstantin H.
Villaruz, Liza C.
Faller, Bryan A.
Al Baghdadi, Tareq
Hines, Susan
Qian, Lu
Minichiello, Katherine
Gandara, David R.
Kelly, Karen
Herbst, Roy S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[45] Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).
Reckamp, Karen L.
Redman, Mary Weber
Dragnev, Konstantin H.
Villaruz, Liza C.
Faller, Bryan A.
Al Baghdadi, Tareq
Hines, Susan
Qian, Lu
Minichiello, Katherine
Gandara, David R.
Herbst, Roy S.
Kelly, Karen
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[46] ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
Padda, Sukhmani Kaur
Redman, Mary Weber
Gerber, David E.
Stinchcombe, Tom
Waqar, Saiama Naheed
Leal, Ticiana
Minichiello, Katherine
Reckamp, Karen L.
Herbst, Roy S.
Borghaei, Hossein
Brahmer, Julie R.
Gray, Jhanelle Elaine
Kelly, Karen
Ramalingam, Suresh S.
Neal, Joel W.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy
Wrangle, John M.
Redman, Mary Weber
Husain, Hatim
Reckamp, Karen L.
Stinchcombe, Tom
Edelman, Martin Joseph
Leal, Ticiana
Faller, Bryan A.
Minichiello, Katherine
Borghaei, Hossein
Kelly, Karen
Herbst, Roy S.
Gray, Jhanelle E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →